26 research outputs found
Studie rozmanitosti HCV IRES: propojenĂ experimentálnĂho pĹ™Ăstupu s pĹ™Ăpravou a hodnocenĂm rozsáhlĂ© databáze mutacĂ
Translation initiation in the hepatitis C virus (HCV) occurs through a cap- independent mechanism that involves an internal ribosome entry site (IRES) capable of interaction with and utilization of the eukaryotic translational machinery. We focused on the structural configuration of the different HCV-IRES domains and the impact of IRES primary sequence variations on secondary structure conservation and function. For this purpose we introduced into our laboratory, methods such as denaturing gradient and temperature gradient gel electrophoresis for screening the degree of heterogeneity and total amount of HCV-IRES variability accumulated in HCV infected patients over a period of time. The selected samples showed variable migration pattern of the HCV-IRES (from all the patients) visualized in DGGE and TGGE, were sequenced and evaluated for translation efficiency using flow cytometry. In some cases, we discovered that multiple mutations, even those scattered across different domains of HCV-IRES, led to restoration of the HCV-IRES translational activity, although the individual occurrences of these mutations were found to be deleterious. We propose that such observation may be attributed to probable long- range inter- and/or intra-domain functional interactions. We established a large-scale HCV-IRES...Iniciace translace u viru hepatitidy C (HCV) probĂhá mechanismem nezávislĂ˝m na ÄŤepiÄŤce, kterĂ˝ vyuĹľĂvá vnitĹ™nĂho vazebnĂ©ho mĂsto pro ribozom (IRES), kterĂ© interaguje s eukaryotnĂm translaÄŤnĂm aparátem a je schopnĂ© jej vyuĹľĂvat. V našem vĂ˝zkumu jsme se zaměřili na strukturnĂ konformaci jednotlivĂ˝ch domĂ©n HCV-IRES a na dopad primárnĂ sekvence IRES na konzervovanost a funkci tĂ©to sekundárnĂ struktury. Za tĂmto účelem byl proveden screening pacientĹŻ infikovanĂ˝ch virem hepatitidy C pro zjištÄ›nĂ mĂry heterogenity a celkovĂ© variability HCV-IRES vzniklĂ© u pacientĹŻ v prĹŻbÄ›hu jejich nemoci pomocĂ optimalizovánĂ metod, jako jsou gelovĂ© elektroforĂ©zy s denaturaÄŤnĂm nebo teplotnĂm gradientem. Účinnost translace mutovanĂ˝ch HCV-IRES sekvencĂ byla měřena pomocĂ prĹŻtokovĂ© cytometrie. V nÄ›kterĂ˝ch pĹ™Ăpadech jsme zjistili, Ĺľe nÄ›kolikanásobnĂ© mutace, vÄŤetnÄ› tÄ›ch, kterĂ© jsou rozesety mezi rĹŻznĂ© domĂ©ny HCV-IRES, vedly k obnovÄ› translaÄŤnĂ aktivity, aÄŤkoli tyto mutace účinnost translace sniĹľovaly, pokud byly analyzovány jednotlivÄ›. Navrhujeme, Ĺľe tato pozorovánĂ by mohla bĂ˝t vysvÄ›tlena potenciálnĂmi mezi- a/nebo vnitro-domĂ©novĂ˝mi funkÄŤnĂmi interakcemi pĹŻsobĂcĂmi na velkou vzdálenost. TakĂ© jsme nalezli novĂ© mutace, jejichĹľ vliv na účinnost translace HCV-IRES byl experimentálnÄ› ověřen. VytvoĹ™enĂ rozsáhlĂ© databáze variacĂ...Department of Genetics and MicrobiologyKatedra genetiky a mikrobiologieFaculty of SciencePĹ™ĂrodovÄ›decká fakult
Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
Background: Parkinson’s disease is an aggressive and progressive neurodegenerative
disorder that depletes dopamine (DA) in the central nervous system. Dopamine replacement
therapy, mainly through actual dopamine and its original prodrug L-dopa (LD), faces many
challenges such as poor blood brain barrier penetration and decreased response to therapy with time.
Methods: The prodrugs described herein are ester, amide, dimeric amide, carrier-mediated, peptide
transport-mediated, cyclic, chemical delivery systems and enzyme-models prodrugs designed and
made by chemical means, and their bioavailability was studied in animals. Results: A promising
ester prodrug for intranasal delivery has been developed. LD methyl ester is currently in Phase
III clinical trials. A series of amide prodrugs were synthesized with better stability than ester
prodrugs. Both amide and dimeric amide prodrugs offer enhanced blood brain barrier (BBB)
penetration and better pharmacokinetics. Attaching LD to sugars has been used to exploit glucose
transport mechanisms into the brain. Conclusions: Till now, no DA prodrug has reached the
pharmaceutical market, nevertheless, the future of utilizing prodrugs for the treatment of PD seems to
be bright. For instance, LD ester prodrugs have demonstrated an adequate intranasal delivery of LD,
thus enabling the absorption of therapeutic agents to the brain. Most of the amide, cyclic, peptidyl or
chemical delivery systems of DA prodrugs demonstrated enhanced pharmacokinetic properties
Recommended from our members
C6orf203 is an RNA-binding protein involved in mitochondrial protein synthesis.
In all biological systems, RNAs are associated with RNA-binding proteins (RBPs), forming complexes that control gene regulatory mechanisms, from RNA synthesis to decay. In mammalian mitochondria, post-transcriptional regulation of gene expression is conducted by mitochondrial RBPs (mt-RBPs) at various stages of mt-RNA metabolism, including polycistronic transcript production, its processing into individual transcripts, mt-RNA modifications, stability, translation and degradation. To date, only a handful of mt-RBPs have been characterized. Here, we describe a putative human mitochondrial protein, C6orf203, that contains an S4-like domain-an evolutionarily conserved RNA-binding domain previously identified in proteins involved in translation. Our data show C6orf203 to bind highly structured RNA in vitro and associate with the mitoribosomal large subunit in HEK293T cells. Knockout of C6orf203 leads to a decrease in mitochondrial translation and consequent OXPHOS deficiency, without affecting mitochondrial RNA levels. Although mitoribosome stability is not affected in C6orf203-depleted cells, mitoribosome profiling analysis revealed a global disruption of the association of mt-mRNAs with the mitoribosome, suggesting that C6orf203 may be required for the proper maturation and functioning of the mitoribosome. We therefore propose C6orf203 to be a novel RNA-binding protein involved in mitochondrial translation, expanding the repertoire of factors engaged in this process
A study of the HCV IRES variability: An experimental approach coupled with design of a large-scale mutation database
Translation initiation in the hepatitis C virus (HCV) occurs through a cap- independent mechanism that involves an internal ribosome entry site (IRES) capable of interaction with and utilization of the eukaryotic translational machinery. We focused on the structural configuration of the different HCV-IRES domains and the impact of IRES primary sequence variations on secondary structure conservation and function. For this purpose we introduced into our laboratory, methods such as denaturing gradient and temperature gradient gel electrophoresis for screening the degree of heterogeneity and total amount of HCV-IRES variability accumulated in HCV infected patients over a period of time. The selected samples showed variable migration pattern of the HCV-IRES (from all the patients) visualized in DGGE and TGGE, were sequenced and evaluated for translation efficiency using flow cytometry. In some cases, we discovered that multiple mutations, even those scattered across different domains of HCV-IRES, led to restoration of the HCV-IRES translational activity, although the individual occurrences of these mutations were found to be deleterious. We propose that such observation may be attributed to probable long- range inter- and/or intra-domain functional interactions. We established a large-scale HCV-IRES..
HCVIVdb: The hepatitis-C IRES variation database
Background: Sequence variability in the hepatitis C virus (HCV) genome has led to the development and classification of six genotypes and a number of subtypes. The HCV 5′ untranslated region mainly comprises an internal ribosomal entry site (IRES) responsible for cap-independent synthesis of the viral polyprotein and is conserved among all HCV genotypes. Description: Considering the possible high impact of variations in HCV IRES on viral protein production and thus virus replication, we decided to collect the available data on known nucleotide variants in the HCV IRES and their impact on IRES function in translation initiation. The HCV IRES variation database (HCVIVdb) is a collection of naturally occurring and engineered mutation entries for the HCV IRES. Each entry contains contextual information pertaining to the entry such as the HCV genotypic background and links to the original publication. Where available, quantitative data on the IRES efficiency in translation have been collated along with details on the reporter system used to generate the data. Data are displayed both in a tabular and graphical formats and allow direct comparison of results from different experiments. Together the data provide a central resource for researchers in the IRES and hepatitis C-oriented fields. Conclusion: The collation of over 1900 mutations enables systematic analysis of the HCV IRES. The database is mainly dedicated to detailed comparative and functional analysis of all the HCV IRES domains, which can further lead to the development of site-specific drug designs and provide a guide for future experiments. HCVIVdb is available at http://www.hcvivdb.org
HCVIVdb: The hepatitis-C IRES variation database
Background: Sequence variability in the hepatitis C virus (HCV) genome has led to the development and classification of six genotypes and a number of subtypes. The HCV 5′ untranslated region mainly comprises an internal ribosomal entry site (IRES) responsible for cap-independent synthesis of the viral polyprotein and is conserved among all HCV genotypes. Description: Considering the possible high impact of variations in HCV IRES on viral protein production and thus virus replication, we decided to collect the available data on known nucleotide variants in the HCV IRES and their impact on IRES function in translation initiation. The HCV IRES variation database (HCVIVdb) is a collection of naturally occurring and engineered mutation entries for the HCV IRES. Each entry contains contextual information pertaining to the entry such as the HCV genotypic background and links to the original publication. Where available, quantitative data on the IRES efficiency in translation have been collated along with details on the reporter system used to generate the data. Data are displayed both in a tabular and graphical formats and allow direct comparison of results from different experiments. Together the data provide a central resource for researchers in the IRES and hepatitis C-oriented fields. Conclusion: The collation of over 1900 mutations enables systematic analysis of the HCV IRES. The database is mainly dedicated to detailed comparative and functional analysis of all the HCV IRES domains, which can further lead to the development of site-specific drug designs and provide a guide for future experiments. HCVIVdb is available at http://www.hcvivdb.org
Structural basis for late maturation steps of the human mitoribosomal large subunit
Mitochondrial ribosomes (mitoribosomes) are characterized by a distinct architecture and thus biogenesis pathway. Here, cryo-EM structures of mitoribosome large subunit assembly intermediates elucidate final steps of 16 S rRNA folding, methylation and peptidyl transferase centre (PTC) completion, as well as functions of several mitoribosome assembly factors
Characterization of Hepatitis C Virus IRES Quasispecies – From the Individual to the Pool
Hepatitis C virus (HCV) is a single-stranded positive-sense RNA virus from the genus Hepacivirus. The viral genomic +RNA is 9.6 kb long and contains highly structured 5′ and 3′ untranslated regions (UTRs) and codes for a single large polyprotein, which is co- and post-translationally processed by viral and cellular proteases into at least 11 different polypeptides. Most of the 5′ UTR and an initial part of the polyprotein gene are occupied by an internal ribosome entry site (IRES), which mediates cap-independent translation of the viral proteins and allows the virus to overcome cellular antiviral defense based on the overall reduction of the cap-dependent translation initiation. We reconsidered published results concerning a search for possible correlation between patient response to interferon-based antiviral therapy and accumulation of nucleotide changes within the HCV IRES. However, we were unable to identify any such correlation. Rather than searching for individual mutations, we suggest to focus on determination of individual and collective activities of the HCV IRESs found in patient specimens. We developed a combined, fast, and undemanding approach based on high-throughput cloning of the HCV IRES species to a bicistronic plasmid followed by determination of the HCV IRES activity by flow cytometry. This approach can be adjusted for measurement of the individual HCV IRES activity and for estimation of the aggregate ability of the whole HCV population present in the specimen to synthesize viral proteins. To detect nucleotide variations in the individual IRESs, we used denaturing gradient gel electrophoresis (DGGE) analysis that greatly improved identification and classification of HCV IRES variants in the sample. We suggest that determination of the collective activity of the majority of HCV IRES variants present in one patient specimen in a given time represents possible functional relations among variant sequences within the complex population of viral quasispecies better than bare information about their nucleotide sequences. A similar approach might be used for monitoring of sequence variations in quasispecies populations of other RNA viruses in all cases when changes in primary sequence represent changes in measurable and easily quantifiable phenotypes
Additional file 1: of HCVIVdb: The hepatitis-C IRES variation database
A list of online databases related to the hepatitis C virus. Sections are categorized based on the content of the database, tools available and the link to the relevant website and publication. (PDF 232Â kb